Haemonetics (HAE) in Pivotal Point Check: Breakthrough in Plasma Business - Strategic CSL Deal Eliminates Cluster Risk!
Reading Time: 3 minutes
Expanded US Partnership: Haemonetics has entered into a new supply agreement with major client CSL Plasma. Comprehensive Technology Rollout: Complete outfitting of US plasma centers with NexSys-PCS devices and Persona-PLUS software planned by the end of 2027. Technical Breakout: The stock marks a new annual high of around 119 USD under significantly increased trading volume. Haemonetics is a medical technology company focused on blood and plasma management. On Thursday, October 8, 2026, the stock jumped over 17% under rising trading...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
